The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
Open accessAbstract
Background: The lack of a general clinic-relevant model for human cancer is a major impediment to the acceleration of novel therapeutic approaches for clinical use. We propose to establish and characterize primary human hepatocellular carcinoma (HCC) xenografts that can be used to evaluate the cytotoxicity of adoptive chimeric antigen receptor (CAR) T cells and accelerate the clinical translation of CAR T cells used in HCC. Methods: Primary HCCs were used to establish the xenografts. The morphology, immunological markers, and gene expression characteristics of xenografts were detected and compared to those of the corresponding primary tumors. CAR T cells were adoptively transplanted into patient-derived xenograft (PDX) models of HCC. The cytotoxicity of CAR T cells in vivo was evaluated. Results: PDX1, PDX2, and PDX3 were established using primary tumors from three individual HCC patients. All three PDX maintained original tumor characteristics in their morphology, immunological markers, and gene expression. Tumors in PDX1 grew relatively slower than that in PDX2 and PDX3. GPC3-CAR T cells efficiently suppressed tumor growth in PDX3 and impressively eradicated tumor cells from PDX1 and PDX2, in which GPC3 proteins were highly expressed. Conclusion: GPC3-CAR T cells were capable of effectively eliminating tumors in PDX model of HCC. Therefore, GPC3-CAR T cell therapy is a promising candidate for HCC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183 · cited 1×
“Previous studies show that MET and CTNNB1 act as oncogenes in HCCs and that CCND1 is the hallmark of cell cycle progression (19, 26, 27).”
BackgroundPatient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
Research works printed but not linked: 27
- Sharma, 2015, CD4+CD25+CD127low regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus associated hepatocellular carcinoma, Front Immunol, 6, 49, 10.3389/fimmu.2015.00049 · DOI
- Page, 2014, Hepatocellular carcinoma: diagnosis, management, and prognosis, Surg Oncol Clin N Am, 23, 289, 10.1016/j.soc.2013.10.006 · DOI
- Jayachandran, 2016, Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma, J Hematol Oncol, 9, 74, 10.1186/s13045-016-0307-9 · DOI · Paper page
- Clavien, 2007, Strategies for safer liver surgery and partial liver transplantation, N Engl J Med, 356, 1545, 10.1056/NEJMra065156 · DOI · Paper page
- Waghray, 2015, Hepatocellular carcinoma: from diagnosis to treatment, World J Hepatol, 7, 1020, 10.4254/wjh.v7.i8.1020 · DOI · Paper page
- Toyoda, 2004, Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan, Cancer, 100, 2415, 10.1002/cncr.20289 · DOI
- Lee, 2012, Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience, Korean J Hepatol, 18, 48, 10.3350/kjhep.2012.18.1.48 · doi:10.3350/kjhep.2012.18.1.48
- Jin, 2010, Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review, Clin Transl Oncol, 12, 473, 10.1007/s12094-010-0540-6 · DOI · Paper page
- Bissig-Choisat, 2016, Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer, J Hepatol, 65, 325, 10.1016/j.jhep.2016.04.009 · DOI
- Huynh, 2006, Xenografts of human hepatocellular carcinoma: a useful model for testing drugs, Clin Cancer Res, 12, 4306, 10.1158/1078-0432.CCR-05-2568 · DOI
- Dargel, 2015, T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice, Gastroenterology, 149, 1042, 10.1053/j.gastro.2015.05.055 · DOI
- Gao, 2014, Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma, Clin Cancer Res, 20, 6418, 10.1158/1078-0432.CCR-14-1170 · DOI · Paper page
- Wenpeng, 2016, Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity, Hum Gene Ther, 10.1089/hum.2016.025 · DOI
- Ye, 2015, Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments, J Hematol Oncol, 8, 59, 10.1186/s13045-015-0156-y · DOI
- Jiang, 2016, Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized, J Hematol Oncol, 9, 94, 10.1186/s13045-016-0310-1 · doi:10.1186/s13045-016-0310-1
- Xiao, 2015, Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells, J Hematol Oncol, 8, 7, 10.1186/s13045-014-0102-4 · DOI
- Nakano, 2007, Anti-Glypican 3 Antibody
- Venepalli, 2013, Targeting the HGF-cMET axis in hepatocellular carcinoma, Int J Hepatol, 2013, 341636, 10.1155/2013/341636 · DOI
- Nault, 2013, A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection, Gastroenterology, 145, 176, 10.1053/j.gastro.2013.03.051 · DOI · Paper page
- Jeannin, 1999, Human effector memory T cells express CD86: a functional role in naive T cell priming, J Immunol, 162, 2044, 10.4049/jimmunol.162.4.2044 · DOI
- Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838 · DOI · Paper page
- Xin, 2014, Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts, PLoS One, 9, e85308, 10.1371/journal.pone.0085308 · DOI
- Zhang, 2002, Polymorphisms in cyclin D1 gene and hepatocellular carcinoma, Mol Carcinog, 33, 125, 10.1002/mc.10028.abs · doi:10.1002/mc.10028.abs
- Domaica, 2009, Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands, EMBO Rep, 10, 908, 10.1038/embor.2009.92 · DOI
- Han, 2013, Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges, J Hematol Oncol, 6, 47, 10.1186/1756-8722-6-47 · DOI
- John, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin Cancer Res, 19, 5636, 10.1158/1078-0432.CCR-13-0458 · DOI · Paper page
- Moon, 2014, Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors, Clin Cancer Res, 20, 4262, 10.1158/1078-0432.CCR-13-2627 · DOI · Paper page
Cited by
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115801 · Cited by 426
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics
Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., Watanabe, H., Franchi, M., Baud, S., Brézillon, S., Götte, M., Passi, A., Vigetti, D., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00354 · Cited by 367
Metadata
- Authors
- Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., Liu, Q., Peng, M., Yu, F., Weng, J., Du, X., Pei, D., Liu, P., Yao, Y., Xue, P., & Li, P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-01-11
- Volume
- 7
- Pages
- 690-690
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2570331434
- Cited by
- 207
- References
- 5
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.3389/fimmu.2016.00690
- The paper
- Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., Liu, Q., Peng, M., Yu, F., Weng, J., Du, X., Pei, D., Liu, P., Yao, Y., Xue, P., & Li, P. (2017). Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2016.00690
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.